Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination.
A case report of impaired exercise tolerance during administration of broxyquinoline-brobenzoxaldine combination in therapeutic doses is presented. The first author of this paper, a 28-year-old healthy male, volunteered as a subject for a prospective study on the neurotoxicity of halogenated hydroxyquinolines and took a course of broxyquinoline-brobenzoxaldine combination. The author, who is a karate enthusiast, observed impairment of exercise tolerance during the course of treatment with the drugs. A challenge course of treatment with the same drugs in the same doses produced similar effects. Since halogenated hydroxyquinolines are still used widely in many countries, such an adverse effect would be of practical relevance, particularly in asymptomatic cyst-passers of Entamoeba histolytica whose occupations involve physical labour.
Swain
R
R
Bapna
J S
JS
D000328:Adult; D004338:Drug Combinations / Q000633:toxicity; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D006912:Hydroxyquinolines / Q000633:toxicity*; D008297:Male; D015125:Oxyquinoline / Q000031:analogs & derivatives / Q000633:toxicity*; D005082:Physical Exertion / Q000187:drug effects*; D011798:Quinaldines / Q000633:toxicity*; D011804:Quinolines / Q000633:toxicity*; D012119:Respiration / Q000187:drug effects
D004338:Drug Combinations; D006912:Hydroxyquinolines; D011798:Quinaldines; D011804:Quinolines; D015125:Oxyquinoline; C001454:brobenzoxaldine, broxyquinoline drug combination